Clinical Research Directory
Browse clinical research sites, groups, and studies.
Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
Sponsor: Scott Silveira
Summary
This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of a patented age-reversal therapy, EGA®, compared to conventional nicotinamide mononucleotide (NMN) supplementation. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults. The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels. EGA® is composed of three metabolomic compounds that are endogenous to humans. The formulation has been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.
Key Details
Gender
All
Age Range
60 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-02-21
Completion Date
2027-01-01
Last Updated
2026-02-20
Healthy Volunteers
Yes
Interventions
NMN, betaine, low-dose hydrogen peroxide (EGA)
Proprietary formulation containing NMN, betaine, and low-dose hydrogen peroxide.
Nicotinamide Mononucleotide (NMN)
Conventional NMN supplement.
Placebo
Organoleptically matched inert control.
Locations (1)
Medical Office of Dr. Robert Huizenga MD
Beverly Hills, California, United States